Peptide Pharmacology Fundamentals
How peptides bind, signal, get destroyed, and get delivered.
What's covered
Click any topic to expand a deeper drill-down with mechanism, key references, and a take-home summary.
By the end of this module you will be able to
- L01Describe why oral bioavailability is the central pharmacology problem for peptides.
- L02Name three half-life-extension strategies and give an example drug for each.
- L03Explain biased agonism with a concrete clinical example (e.g. semaglutide vs older GLP-1 RAs).
What you should walk away believing
Click any takeaway to open a full AI-generated lesson with mechanism, examples, evidence grading, counseling scripts, pearls, references, and a self-check.
What this means for you
Most peptide drugs need to be injected because the gut destroys them. Newer ones last days or weeks per dose because chemists attached fatty acids that make them stick to a blood protein called albumin.
Understanding why semaglutide is once-weekly while exenatide-immediate-release was twice-daily comes down to lipidation and albumin half-life extension. Antibody formation is a real but usually clinically minor issue with peptide drugs; it matters most for repeated-use replacement peptides like insulin analogs.
Biased agonism (e.g., GLP-1R β-arrestin vs cAMP) is now an active design principle. Tirzepatide's GIP/GLP-1 dual agonism shows non-trivial GIP partial agonism contributes to efficacy — the dual mechanism isn't just additive.
Visual reference
All peptides need refrigeration and degrade in days.
Many modern peptide drugs (semaglutide pen) are stable at room temperature for weeks once in use. Stability depends on formulation, not 'peptide-ness'.
What the data say
Test yourself
Lock it in — review what's due
Key terms & abbreviations
- GPCRG-protein coupled receptor
- Most common peptide-drug target class. Includes GLP-1R, GIPR, glucagon receptor, oxytocin receptor, opioid receptors, somatostatin receptors.
- Lipidation
- Covalent attachment of a fatty acid moiety to a peptide to enable albumin binding and extend half-life.
- Biased agonism
- Selective activation of one downstream pathway (e.g., G-protein vs β-arrestin) over another at the same receptor.
- Tachyphylaxis
- Rapid loss of response with repeated dosing — relevant to GnRH agonists and some peptide hormones.
Sources cited in this module
- [1]ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA OriginFDA Guidance for Industry · 2021Regulatory · T1
- [2]CDER/CBER classification: peptides ≤40 aa regulated as drugsU.S. FDA Federal Register Notice · 2020Regulatory · T1
- [3]Therapeutic peptides: current applications and future directionsWang L. et al. · Signal Transduction and Targeted Therapy · 2022Review · T2
- [4]The discovery and development of liraglutide and semaglutideKnudsen LB, Lau J. · Frontiers in Endocrinology · 2019Review · T2
- [5]Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutideLau J. et al. · Journal of Medicinal Chemistry · 2015Mechanism / preclinical · T2